Market capitalization | $9.23b |
Enterprise Value | $9.67b |
P/E (TTM) P/E ratio | 102.30 |
EV/FCF (TTM) EV/FCF | 19.13 |
EV/Sales (TTM) EV/Sales | 4.83 |
P/S ratio (TTM) P/S ratio | 4.61 |
P/B ratio (TTM) P/B ratio | 2.71 |
Dividend yield | 3.64% |
Last dividend (FY25) | $1.55 |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
24 Analysts have issued a QIAGEN NV forecast:
24 Analysts have issued a QIAGEN NV forecast:
Mar '25 |
+/-
%
|
||
Revenue | 2,003 2,003 |
3%
3%
|
|
Gross Profit | 1,271 1,271 |
5%
5%
|
|
EBITDA | 715 715 |
10%
10%
|
EBIT (Operating Income) EBIT | 522 522 |
18%
18%
|
Net Profit | 94 94 |
72%
72%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Head office | Netherlands |
CEO | Thierry Bernard |
Employees | 5,765 |
Founded | 1996 |
Website | www.qiagen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.